fbpx
Connect with us

News

Prime Minister visits North East diagnostic company

Published

on

The Q-POC™ is a simple-to-use diagnostics test

QuantuMDx Group Limited, a UK-based diagnostics company which has developed a revolutionary 30 minute PCR diagnostics device, Q-POC™, and accompanying SARS-CoV-2 test, welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne, this weekend. 

Q-POC™ is an innovative portable, Polymerase Chain Reaction (‘PCR’) device offering lab-standard diagnostic testing as the patient waits, with swab-to-result in 30 minutes. This is the same time as a lateral flow test but with PCR accuracy. The Q-POCTM has been designed for rapid PCR testing in clinical settings to ensure the safety of our NHS frontline healthcare workers. 

The simple-to-use test (insert cassette and press go) will be rolled out in a wide range of settings – from emergency rooms, hospital triage ICU, test-and-trace initiatives to pharmacies and clinics – rapidly and without the need for a laboratory. The Q-POC™ has just completed its evaluation by the Technology Validation Group (TVG) of the NHS and results will be published shortly. 

The Q-POC™ device was designed and is now manufactured in the UK, representing the best of British innovation. This was made possible with a £16m grant from Her Majesty’s Government, which allowed the company to accelerate its manufacturing programme.

The Q-POC™ system has this week been made available for research use only (RUO) and the company expects to receive CE-IVD marking in the summer. As the device represents a significant advance on rapid and portable PCR testing, the company is anticipating strong sales and is already in talks with a wide range of customers including airports, private healthcare, pharmacies and overseas health ministries. 

The company’s first commercial test for Q-POC™ will detect SARS-CoV-2 and all known variants, including South African, Kent and Brazil. 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories